Trending...
- Memelinked Social Media powered by cryptocurrency launching July 2026 - 257
- Transcure Responds to CMS Removal of 285 Inpatient-Only Procedures - 132
- JiT Home Buyers Strengthens Multi-State Presence as Demand for Flexible Home Selling Solutions Grows - 122
CASTRES, France - Californer -- A research team specialized in the study of nervous system disorders has found that NLX-112, a serotonin 5-HT1A receptor agonist developed by Neurolixis, reversed motor deficits in a transgenic model of Spinocerebellar ataxia3 (SCA3), a rare genetic orphan disease. The team led by Prof. Patricia Maciel, at the University of Minho, Portugal, reported online in the journal, Neurobiology of Disease, that NLX-112 restored motor function in nematode worms that express the same gene mutation as that seen in SCA3 patients.
Prof. Maciel commented: "SCA3, also known as Machado-Joseph disease, is an inherited condition. Symptoms including clumsiness, loss of strength, and tremor in the arms and legs that worsen over time, eventually leading to very severe disability. Our new data suggest that NLX-112 may improve the condition of patients suffering from this debilitating disorder."
Neurolixis is now collaborating with Prof. Maciel's team to test NLX-112 in transgenic SCA3 mice. The project, supported by the US Dept. of Defense, will determine whether extended NLX-112 administration attenuates SCA3 symptoms and slows down their development.
More on The Californer
Adrian Newman-Tancredi, CEO of Neurolixis commented: "SCA3 is incurable and there is no approved treatment. If the results seen in the transgenic nematode worm model are translated to transgenic SCA3 mice, Neurolixis will seek to develop NLX-112 in clinical trials for SCA3 patients. NLX-112 has previously been tested in over 500 patients for other indications so we know it is safe and well tolerated."
NLX-112 is currently undergoing a clinical Phase 2A study for treatment of L-DOPA-induced dyskinesia in Parkinson's disease patients and the new SCA3 data suggests that it may also have utility for treatment of additional movement disorders.
Full publication – Open Access
Identification of the 5-HT1A serotonin receptor as a novel therapeutic target in a C. elegans model of Machado-Joseph disease.
Pereira-Sousa et al., Neurobiology of Disease, 28 Jan 2021 (Online ahead of print)
doi: 10.1016/j.nbd.2021.105278, PMID: 33516872
About Neurolixis
Neurolixis is a privately held biotechnology company developing therapies for central nervous system disorders. It has two lead compounds, NLX‑112 (Phase 2) which targets treatment of motor disorders, and NLX-101 (Phase 1), a potential rapid-acting anti-depressant, with utility for treating neuro-developmental disorders including Rett syndrome. In addition, Neurolixis conducts a drug discovery program targeting chronic pain (non-opioid mechanism) and depression.
More on The Californer
About the University of Minho
The mission of University of Minho, founded in 1973, is to create, spread and convert knowledge into value-generating applications. The Life and Health Sciences Research Institute (ICVS) is the Biomedicine R&D Unit of the School of Medicine cluster of the University. The cluster includes 2CA-Braga, a clinical research site that currently runs 1/3 of all clinical trials in Portugal; P5, that with the ICVS conceives and develops new digital medicine products and provides medical services with a digital interface; and B.ACIS, a knowledge transfer interface fostering developments in biomedical research resulting in marketed products that bring clinical benefits to patients.
Prof. Maciel commented: "SCA3, also known as Machado-Joseph disease, is an inherited condition. Symptoms including clumsiness, loss of strength, and tremor in the arms and legs that worsen over time, eventually leading to very severe disability. Our new data suggest that NLX-112 may improve the condition of patients suffering from this debilitating disorder."
Neurolixis is now collaborating with Prof. Maciel's team to test NLX-112 in transgenic SCA3 mice. The project, supported by the US Dept. of Defense, will determine whether extended NLX-112 administration attenuates SCA3 symptoms and slows down their development.
More on The Californer
- For True Confessions Day:Confessions told from Video Tombstones and a book called "Cemetery of Lies"
- Snell & Wilmer Welcomes Associate Anjel Bonilla to the Los Angeles Office
- SEEAG's Free "Farm Day Every Day" At Tutti Frutti Farms – March 28 in Lompoc
- DINERO GRATIS PARA LA UNIVERSIDAD: Nuevo esfuerzo conecta a estudiantes de colegios comunitarios en California con becas disponibles de CalKIDS
- Williamsville Spa Expands Team to Meet Growing Demand for Professional Facials
Adrian Newman-Tancredi, CEO of Neurolixis commented: "SCA3 is incurable and there is no approved treatment. If the results seen in the transgenic nematode worm model are translated to transgenic SCA3 mice, Neurolixis will seek to develop NLX-112 in clinical trials for SCA3 patients. NLX-112 has previously been tested in over 500 patients for other indications so we know it is safe and well tolerated."
NLX-112 is currently undergoing a clinical Phase 2A study for treatment of L-DOPA-induced dyskinesia in Parkinson's disease patients and the new SCA3 data suggests that it may also have utility for treatment of additional movement disorders.
Full publication – Open Access
Identification of the 5-HT1A serotonin receptor as a novel therapeutic target in a C. elegans model of Machado-Joseph disease.
Pereira-Sousa et al., Neurobiology of Disease, 28 Jan 2021 (Online ahead of print)
doi: 10.1016/j.nbd.2021.105278, PMID: 33516872
About Neurolixis
Neurolixis is a privately held biotechnology company developing therapies for central nervous system disorders. It has two lead compounds, NLX‑112 (Phase 2) which targets treatment of motor disorders, and NLX-101 (Phase 1), a potential rapid-acting anti-depressant, with utility for treating neuro-developmental disorders including Rett syndrome. In addition, Neurolixis conducts a drug discovery program targeting chronic pain (non-opioid mechanism) and depression.
More on The Californer
- BrassTranscripts Launches Self-Service Bulk Transcription with Volume Pricing
- AI-Designed Diffractive Optical Processors Pave the Way for Low-Power Structural Health Monitoring
- California: Governor Newsom announces over $2 million in funding for small businesses innovating in the Golden State
- California: Governor, Senate, Assembly commit to protecting elections from Trump's federal overreach
- FREE MONEY FOR COLLEGE: New effort connects California community college students with available CalKIDS scholarships
About the University of Minho
The mission of University of Minho, founded in 1973, is to create, spread and convert knowledge into value-generating applications. The Life and Health Sciences Research Institute (ICVS) is the Biomedicine R&D Unit of the School of Medicine cluster of the University. The cluster includes 2CA-Braga, a clinical research site that currently runs 1/3 of all clinical trials in Portugal; P5, that with the ICVS conceives and develops new digital medicine products and provides medical services with a digital interface; and B.ACIS, a knowledge transfer interface fostering developments in biomedical research resulting in marketed products that bring clinical benefits to patients.
Source: NEUROLIXIS
0 Comments
Latest on The Californer
- City of Long Beach Announces Departure of Director of Technology and Innovation Department
- Seven-Year-Old Toronto Dancer Julianna Selivanov Wins Nine Medals at Quebec Championship and Reaches Finals at UK Dance Festival
- Alexander Rossi and Mayor Bob Foster to be Inducted into 20th Anniversary Long Beach Motorsports Walk of Fame
- California: Governor Newsom orders flags at half-staff as Reverend Jesse Jackson laid to rest
- The Reckless Unleash Blistering New Single "OBLIVION"
- Wordly Enhances Microsoft Teams Translation for Faster Multilingual Meetings for Global Enterprises
- JiT Home Buyers Provides Guidance for Families Navigating Inherited Homes Nationwide
- New Travel Guide: "Four Adventure-Packed Days in Lausanne, Switzerland
- Progressive Dental & The Closing Institute Partner with Zest Dental Solutions to Elevate Full-Arch Growth and Patient Outcomes
- SBRPA To File Legal Challenge To Halt Temporary Santa Barbara Rent Freeze Ordinance
- Long Beach Health Department Expands Fentanyl Test Kit Program to Include Mail-Based Delivery
- SEEAG Gets Go-Ahead To Create New 3.63-Acre Educational Farm in Oxnard
- California: Governor Newsom announces appointments 3.3.2026
- Why Modera is Uniquely Qualified to Serve Emerging Healthcare Models
- Governor Newsom, First Partner Siebel Newsom announce new inductees to the California Hall of Fame
- Spring Surge in 55+ Communities: What Buyers and Sellers Need to Know in 2026
- Jason Caras Launches The Caras Institute Following Successful Exit from IT Authorities
- NuCicer & Stricks Ag Launch Strategic Partnership to Scale High-Protein Chickpeas to Meet Immediate
- Serina Damesworth Hired as Century Fasteners Corp. – Director of Quality
- JiT Home Buyers Emphasizes Transparency and Clear Communication in Direct Home Sales Nationwide